MSFP
NVCR icon

Mark Sheptoff Financial Planning’s NovoCure NVCR Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$15K – 471
2021
Q4 		$15K Buy
+200
New +$20.1K 0.01% 281

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mark Sheptoff Financial Planning's NVCR Position: Q1 2022 in Review

Mark Sheptoff Financial Planning sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 200 shares — an estimated $15K sold.

Mark Sheptoff Financial Planning first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • Mark Sheptoff Financial Planning reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 200 NovoCure shares in Q1 2022, an estimated $15K.
  • Mark Sheptoff Financial Planning first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
  • Mark Sheptoff Financial Planning's NovoCure position peaked at $15K in Q4 2021.
  • 308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2022, filed 12 May 2022.